J Nordanstig, CA Behrendt, I Baumgartner… - European Journal of …, 2024 - Elsevier
BIOTRONIK's First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularisation of …
Objective Despite societal guidelines that peripheral vascular intervention (PVI) should not be the first-line therapy for intermittent claudication, a significant number of patients will …
WC Members, HL Gornik, HD Aronow… - Journal of the American …, 2024 - Elsevier
Abstract Aim The “2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease” provides …
J Froud, M Landin, A Wafi, S White, L Bearne… - Annals of Vascular …, 2024 - Elsevier
Objective Intermittent claudication (IC) is a common pathology, affecting 4.5% of the UK population, and is associated with significant health burden if disease progresses to chronic …
Objective: The aim was to analyze the risk of progression to chronic limb-threatening ischemia (CLTI), amputation and subsequent interventions after revascularization versus …
Objectives The treatment for chronic limb-threatening ischemia (CLTI) has changed dramatically in the last few decades with a shift toward an endovascular-first approach and …
Objective Despite societal guidelines that peripheral vascular intervention (PVI) should not be the first-line therapy for intermittent claudication, a significant number of patients will …
Background: There are limited data supporting or opposing the use of infrapopliteal peripheral vascular interventions (PVI) for the treatment of claudication. Objectives: We …